Dalhousie University
Program Director: Anita Smith, This email address is being protected from spambots. You need JavaScript enabled to view it.
Administrative Staff: Michelle Pineau, This email address is being protected from spambots. You need JavaScript enabled to view it.
Website: https://medicine.dal.ca/departments/department-sites/obstetrics/education/fellowships.html
Length of Program: 2 years
Accepting trainees every 2 years
Application Deadline: application deadline May 30 and decision date June 30 of the year before fellowship start
Documents Required: *see website (Postgrad application form; CV; letter of intent; 3 references; postgrad director letter)

McGill University
Program Director: Dr. Lisa Merovitz, This email address is being protected from spambots. You need JavaScript enabled to view it.
Admistrative Staff: Dolly Rabbath, Lisa Campbell, This email address is being protected from spambots. You need JavaScript enabled to view it.
Length of Program: 2 years
Accepting trainees every year
Application Deadline: May 15 and decision date June 30 of the year before fellowship start
Documents Required: Required documents are listed on the following website - https://www.mcgill.ca/pgme/fellowships/admissions,
CV, personal statement, 3 reference letters. A specialty Certificate if they have completed the program and a letter of standing from the Program Director.
Additional Note: Funding is available for a fellow for the years 2024-2026

McMaster University
Program Director: Dr. Ola Malabarey, 905-521-2100 ext. 76252
Administrative Staff: Heather Shiskoski, This email address is being protected from spambots. You need JavaScript enabled to view it.
Length of Program: 2 years
Accepting trainees every 2 years
Application Deadline: May 30 and decision date June 30 of the year before fellowship start
Documents Required: https://pgme.mcmaster.ca/apply/fellowships-application/

Schulich School of Medicine and Dentistry, Western University
Program Director: Dr. Queena Chou, This email address is being protected from spambots. You need JavaScript enabled to view it., Tel: (519) 646-6343
Administrative Staff: Samantha Kreamer, This email address is being protected from spambots. You need JavaScript enabled to view it. and Nicole Filson: This email address is being protected from spambots. You need JavaScript enabled to view it., Tel: (519) 685-8500 Ext 56362
Website: https://www.schulich.uwo.ca/obsgyn/education/fellowship_programs/urogynaecology.html
Length of program: 2 years
Accepting trainees every year
Application Deadline: May 30 and decision date June 30 of the year before fellowship start
Documents Required: Candidate Letter of Intent/Personal Statement, CV, 3 Letters of Reference
Additional Notes: Funding is available although individualized based on situation of the candidate (i.e., self-funded by sponsoring agency or not)

University of Alberta (Edmonton)
Program Director: Dr. Erin Kelly, This email address is being protected from spambots. You need JavaScript enabled to view it.
Administrative Staff: Tracey Curtis, This email address is being protected from spambots. You need JavaScript enabled to view it. 
Website: https://www.ualberta.ca/obstetrics-gynecology/education-programs/fellowship-and-postdoc-opportunities/female-pelvic-medicine-fellowship/index.html
Length of program: 2 years
Accepting trainees every 2 years
Application Deadline: May 30 and decision date June 30 of the year before fellowship start
Documents required for application: Application Process
Additional notes for applicants: Overview and Funding and Financial Support

University of British Columbia
Program Director: Roxana Geoffrion, This email address is being protected from spambots. You need JavaScript enabled to view it.
Administrative Staff: Mamta Rohra, This email address is being protected from spambots. You need JavaScript enabled to view it. 
Website: https://obgyn.ubc.ca/education/advanced-training-programs/fpmrs/
Length of Program: 2 years
Accepting 1 fellow every 2 years, next start for July 1, 2024
Application Deadline: May 30 and decision date June 30 of the year before fellowship start
Documents Required: Letter of intent, CV, 3 reference letters
Additional Notes: One-month electives in urogynecology at UBC are encouraged prior to application

University of Calgary
Program Director: Dr. Erin Brennand
Administrative Staff: Katiane Ummels, This email address is being protected from spambots. You need JavaScript enabled to view it.
Accepting fellows every 1 year, with some flexibility available for start dates between July and December
Application Deadline: May 30 and decision date June 30 of the year before fellowship start
Documents Required: CV, 3 Letters of Reference, Letter of Application explaining interest in Urogyne program

Université de Montréal
Program Director: Dr. Barbara Reichetzer, This email address is being protected from spambots. You need JavaScript enabled to view it. 
Administrative Staff: Sandra Charland, This email address is being protected from spambots. You need JavaScript enabled to view it., 514 890-8000, poste 32593
Website: https://deptobsgyn.umontreal.ca/etudes/stages-de-perfectionnement/urogynecologie-et-chirurgie-de-reconstruction-du-plancher-pelvien/
Length of Program: 2 years
Accepting trainees every 2 years
Application Deadline: May 30 and decision date June 30 of the year before fellowship start
Documents Require: Recommendation Letter, Motivation Letter, Resume

University of Ottawa / The Ottawa Hospital
Program Director: Hisham Khalil, BSc, MD, FRCSC, This email address is being protected from spambots. You need JavaScript enabled to view it.
Administrative Staff: Erica Moore, This email address is being protected from spambots. You need JavaScript enabled to view it.
Length of Program: 2 years
Accepting trainees every year
Application Deadline: May 30 and decision date June 30 of the year before fellowship start
Documents Required: 3 reference letters, letter of intent, CV

University of Toronto Urogynecology fellowship
Mount Sinai Hospital Urogynecology fellowship
Sunnybrook Urogynecology fellowship
Program Directors: Patricia Lee, This email address is being protected from spambots. You need JavaScript enabled to view it.; Danny Lovatsis, This email address is being protected from spambots. You need JavaScript enabled to view it.
Administrative Staff: Maureen, This email address is being protected from spambots. You need JavaScript enabled to view it.
Website: http://urogyne.ca/program-descriptions-application/#uoft
Length of program: 2 years
Accepting trainees: Typically, every year for the Joint Fellowship (variable for the Mt Sinai site only or Sunnybrook site only fellowships)
Application deadline: May 30 and decision date June 30 of the year before fellowship start
Documents required for application LOI, CV, 3 references and application form: https://obgyn.utoronto.ca/application-guidelines-and-document-checklist

Quebec Universities

Research Spotlight

Research Highlights

• Dr. Maryse Larouche (Urogynecologist, McGill University), and Dr. Roxana Geoffrion (Urogynecologist, University of British Columbia) undertook a systematic review of apical prolapse surgical procedures. They published their systematic review and meta-analysis in Obstetrics &Gynecology (journal of the American College of Obstetricians and Gynecologists/ACOG).

  Sixty-two articles were included in the review. At 1 to 5 years after surgery, the authors reported that (1) There was more anatomic recurrence after sacrocolpopexy than vaginal suspensions; (2)  Minimally invasive sacrocolpopexy showed less overall anatomic recurrence than open sacrocolpopexy, but subjective outcomes were similar; (3) Hysterectomy and suspension vs. hysteropexy seemed to have similar outcomes in the short to medium term. Overall, outcome reporting of studies needs to be improved to allow meaningful comparisons of procedures. The Society of Obstetricians and Gynaecologists of Canada (SOGC) guideline No. 413 was developed based on this review and published in the JOGC.

  View publications:

  Systematic review: https://pubmed.ncbi.nlm.nih.gov/33957652/ 

  SOGC guideline: https://pubmed.ncbi.nlm.nih.gov/33548503/

• Melanie Morin (Physiotherapist, PhD, University of Sherbrooke), Chantal Dumoulin (Physiotherapist, PhD, University of Montreal) and their colleagues published the results of a multicenter randomized controlled trial on treatment options for provoked vestibulodynia in the American Journal of Obstetrics and Gynecology. This research was funded by CIHR and FRQS . The authors recruited and randomized 212 women with provoked vestibulodynia and compared weekly multimodal physical therapy vs. overnight topical lidocaine (5% ointment) treatment (duration – 10 weeks). They found that physical therapy was more effective than lidocaine at reducing intensity of dyspareunia, and at improving sexual function. 195 (92%) patients completed 6-month follow-up. Overall, most women (79%) reported being very much or much improved after physical therapy vs. a minority (39%) of the lidocaine group (p<0.001).

  View publication: https://pubmed.ncbi.nlm.nih.gov/32818475/

2020-2021 Publication List

Larouche M, Belzile E, Geoffrion G. Surgical Management of Symptomatic Apical Pelvic Organ Prolapse: A Systematic Review and Meta-analysis. Obstet Gynecol 2021;137(6). doi: 10.1097/AOG.0000000000004393. [Epub ahead of print] PMID:

Geoffrion R, Larouche M. Guideline No. 413: Surgical Management of Apical Pelvic Organ Prolapse in Women. J Obstet Gynaecol Can. 2021 Apr;43(4):511-523.e1. doi: 10.1016/j.jogc.2021.02.001. Epub 2021 Feb 3. PMID: 33548503.

Roch M, Gaudreault N, Cyr MP, Venne G, Bureau NJ,Morin M. The Female Pelvic Floor Fascia Anatomy: A Systematic Search and Review. Life (Basel). 2021 Aug 30;11(9):900. doi: 10.3390/life11090900. PMID:34575049.

Thalmann M, Ringli L, Adcock M, Swinnen N, de Jong J, Dumoulin C, Guimarães V, de Bruin ED. Usability Study of a Multicomponent Exergame Training for Older Adults with Mobility Limitations. Int J Environ Res Public Health. 2021 Dec 20;18(24):13422. doi: 10.3390/ijerph182413422. PMID:34949028

Geoffrion R, Koenig NA, Zheng M, Sinclair N, Brotto L, Lee T, Larouche M. Preoperative depression and anxiety impact on inpatient surgery outcomes: A prospective cohort study. Ann Surg Open. 2021 Mar;2(1):e049. doi: 10.1097/AS9.0000000000000049.

Frawley H, Shelly B,Morin M, Bernard S, Bø K, Digesu GA, Dickinson T, Goonewardene S, McClurg D, Rahnama'i MS, Schizas A, Slieker-Ten Hove M, Takahashi S, Voelkl Guevara J. An International Continence Society (ICS) report on the terminology for pelvic floor muscle assessment. Neurourol Urodyn. 2021 Jun;40(5):1217-1260. doi: 10.1002/nau.24658. PMID:

Morin M,Dumoulin C, Bergeron S, Mayrand MH, Khalifé S, Waddell G, Dubois MF; PVD Study Group. Multimodal physical therapy versus topical lidocaine for provoked vestibulodynia: a multicenter, randomized trial. Am J Obstet Gynecol. 2021 Feb;224(2):189.e1-189.e12. doi: 10.1016/j.ajog.2020.08.038. PMID:32818475.

Capmas P, Larouche M, Suhartana E. Conversion rate of laparoscopic or robotic to open sacrocolpopexy: are there associated factors and complications? Int Urogynecol J. 2020 Oct 26. doi: 10.1007/s00192-020-04570-4.[Epub ahead of print] PMID: 33104825. 

Larouche M, Albert AYK, Lipsky N, Walmsley S, Loutfy M, Smaill F, Trottier S, Bitnun A, Yudin MH, Cundiff GW, Money DM. Urinary Symptoms and Quality of Life in Women Living With HIV: A Cross-Sectional Study. Int Urogynecol J.2021 Feb;32(2):353-358. doi: 10.1007/s00192-020-04343-z.Epub 2020 May 22. PMID: 32440885.

Le Berre M,Presse N,Morin M, Larouche M, Campeau L, Hu YX, Reid I, Dumoulin C. What do we really know about the role of caffeine on urinary tract symptoms? A scoping review on caffeine consumption and lower urinary tract symptoms in adults. Neurourol Urodyn. 2020 Jun;39(5):1217-1233. doi: 10.1002/nau.24344. Epub 2020 Apr 9. PMID: 32270903.

Bentaleb J, Larouche M. Innovative use of artificial intelligence in urogynecology. Int Urogynecol J. 2020 Jul;31(7):1287-1288.doi: 10.1007/s00192-020-04243-2. Epub 2020 Feb 13. PMID: 32055869.

Cacciari LP, Kruger J, Goodman J, Budgett D, Dumoulin C. Reliability and validity of intravaginal pressure measurements with a new intravaginal pressure device: The FemFit®. Neurourol Urodyn. 2020 Jan;39(1):253-260. doi: 10.1002/nau.24179. Epub 2019 Oct 6. PMID:31588623

Lisonkova S, Geoffrion R, Sanaee M, Muraca GM, Wen Q, Yong PJ, Larouche M, Cundiff GW. Regional variation and temporal trends in surgery for pelvic organ prolapse in Canada, 2004-2014. J Obstet Gynaecol Can. 2020 Jul;42(7):846-852.e5. doi: 10.1016/j.jogc.2019.12.016. Epub 2020 Mar 12. PMID: 32173237.

El-Sayegh B, Dumoulin C, Ali M, Assaf H, Sawan M. A Dynamometer-based Wireless Pelvic Floor Muscle Force Monitoring. Annu Int Conf IEEE Eng Med Biol Soc. 2020 Jul;2020:6127-6130. doi: 10.1109/EMBC44109.2020.9176660. PMID:33019369

Cacciari LP, Amorim AC, Pássaro AC, Dumoulin C, Sacco ICN. Intravaginal pressure profile of continent and incontinent women. J Biomech. 2020 Jan 23;99:109572. doi: 10.1016/j.jbiomech.2019.109572. PMID:31931973

Swinnen N, de Bruin ED, Dumoulin C, Thalmann M, Guimarães V, De Jong J, Vandenbulcke M, Vancampfort D. The VITAAL Stepping Exergame Prototype for Older Adults With Major Neurocognitive Disorder: A Usability Study. Front Aging Neurosci. 2021 Nov 4;13:701319. doi: 10.3389/fnagi.2021.701319. eCollection 2021. PMID:

Pedofsky L, Nielsen PMF, Budgett D, Nemec K, Dumoulin C, Kruger J. Using codesign to develop a mobile application for pelvic floor muscle training with an intravaginal device (femfit®). Neurourol Urodyn. 2021 Nov;40(8):1900-1907. doi: 10.1002/nau.24775. Epub 2021 Aug 31. PMID:

Padoa A, McLean L,Morin M, Vandyken C. The Overactive Pelvic Floor (OPF) and Sexual Dysfunction. Part 2: Evaluation and Treatment of Sexual Dysfunction in OPF Patients. Sex Med Rev. 2021 Jan;9(1):76-92. doi: 10.1016/j.sxmr.2020.04.002. PMID:32631813.

Padoa A, McLean L,Morin M, Vandyken C. "The Overactive Pelvic Floor (OPF) and Sexual Dysfunction" Part 1: Pathophysiology of OPF and Its Impact on the Sexual Response. Sex Med Rev. 2021 Jan;9(1):64-75. doi: 10.1016/j.sxmr.2020.02.002.PMID:32238325.

Paquin MH, Duclos C, Lapierre N, Dubreucq L, Morin M, Meunier J, Rousseau J, Dumoulin C. The effects of a strong desire to void on gait for incontinent and continent older community-dwelling women at risk of falls. Neurourol Urodyn. 2020 Feb;39(2):642-649. doi: 10.1002/nau.24234. Epub 2019 Nov 25. PMID:31765490

Dumoulin C, Morin M, Danieli C, Cacciari L, Mayrand MH, Tousignant M, Abrahamowicz M; Urinary Incontinence and Aging Study Group. Group-Based vs Individual Pelvic Floor Muscle Training to Treat Urinary Incontinence in Older Women: A Randomized Clinical Trial. JAMA Intern Med. 2020 Oct 1;180(10):1284-1293. doi: 10.1001/jamainternmed.2020.2993.PMID:32744599

Cyr MP,Dumoulin C, Bessette P, Pina A, Gotlieb WH, Lapointe-Milot K, Mayrand MH, Morin M. Feasibility, acceptability and effects of multimodal pelvic floor physical therapy for gynecological cancer survivors suffering from painful sexual intercourse: A multicenter prospective interventional study. Gynecol Oncol. 2020 Dec;159(3):778-784. doi: 10.1016/j.ygyno.2020.09.001. PMID:33010968 

Benoit-Piau J,Dumoulin C, Carroll MS, Mayrand MH, Bergeron S, Khalifé S, Waddell G, Morin M; Provoked Vestibulodynia (PVD) Study Group. Efficiency and Cost: E-Recruitment Is a Promising Method in Gynecological Trials. J Sex Med. 2020 Jul;17(7):1304-1311. doi: 10.1016/j.jsxm.2020.04.005. PMID:32434709

Dumoulin C, Cacciari L, Mayrand MH. Implementing Group-Based Pelvic Floor Muscle Training in Clinical Practice-Reply. JAMA Intern Med. 2021 Mar 1;181(3):406-407. doi: 10.1001/jamainternmed.2020.7110. PMID:33315042.

Cyr MP,Dumoulin C, Bessette P, Pina A, Gotlieb WH, Lapointe-Milot K, Mayrand MH, Morin M. Changes in pelvic floor morphometry and muscle function after multimodal physiotherapy for gynaecological cancer survivors suffering from dyspareunia: a prospective interventional study. 2022 Mar;114:54-62. doi: 10.1016/j.physio.2021.09.003. PMID:35093737.

Cyr MP,Dumoulin C, Bessette P, Pina A, Gotlieb WH, Lapointe-Milot K, Mayrand MH, Morin M. A Prospective Single-Arm Study Evaluating the Effects of a Multimodal Physical Therapy Intervention on Psychosexual Outcomes in Women With Dyspareunia After Gynecologic Cancer. J Sex Med. 2021 May;18(5):946-954. doi: 10.1016/j.jsxm.2021.02.014. PMID:33931347 

Cyr MP,Dumoulin C, Bessette P, Pina A, Gotlieb WH, Lapointe-Milot K, Morin M.Characterizing Pelvic Floor Muscle Function and Morphometry in Survivors of Gynecological Cancer Who Have Dyspareunia: A Comparative Cross-Sectional Study. Phys Ther. 2021 Apr 4;101(4):pzab042. doi: 10.1093/ptj/pzab042.PMID:

Cacciari LP, Morin M, Mayrand MH, Tousignant M, Abrahamowicz M,Dumoulin C. Pelvic floor morphometrical and functional changes immediately after pelvic floor muscle training and at 1-year follow-up, in older incontinent women. Neurourol Urodyn. 2021 Jan;40(1):245-255. doi: 10.1002/nau.24542. PMID:33075192

McGill University 

Research Spotlight

Publication Highlight

Covarrubias C, Cammisotto PG, Shamout S, Campeau L. Decrease in the ratio proBDNF/BDNF in the urine of aging female patients with OAB. Metabolites 2023 Jun 3;13(6):723.  PMID: 37367881. DOI: 10.3390/metabo13060723

An indisputable link exists between neurotrophins and growth factors (i.e., nerve growth factor/NGF, its precursor, proNGF), and overactive bladder syndrome (OAB). Thus, the team of Dr Lysanne Campeau, Associate Professor of Surgery at McGill University, first aimed to develop a non-invasive tool for diagnosing OAB syndrome in the urine of aging women. MicroRNAs related to NGF and proNGF metabolism (miR-491-5p and miR-592) that negatively control the translation of the matrix metalloproteinase-9 (MMP-9, the primary enzyme degrading NGF) were detected in void urine. Levels of miR-491-5p, the main miRNA that downregulates MMP-9 synthesis, were significantly decreased in urine from OAB patients. Next, concentrations of brain-derived neurotrophic factor (BDNF) and its precursor (proBDNF) were measured in the urine of a cohort of aging female patients with OAB. The ratio of proBDNF/BDNF was significantly decreased in the OAB group, while the level of MMP-9, the enzyme that cleaves proBDNF into BDNF, was increased in OAB compared to controls. These results suggest that neurotrophins are regulated at the levels of proteolytic enzymes converting pro-form to mature form rather than the translational levels; the ratio proBDNF/BDNF could be useful in the phenotyping of OAB in an aging population, and the difference could originate from enhanced MMP-9 enzymatic activity. Their studies confirm the diagnostic and phenotyping value of the urinary ratio proBDNF over mature BDNF. 

2022-2023 Publication List

Kakkar A, Reuveni-Salzman A, Bentaleb J, Belzile E, Merovitz L, Larouche M. Adverse events associated with pessary use over one year among women attending a pessary care clinic. Int Urogynecol J. 2023. Aug;34(8):1765-1770. PMID: 36715742. IF 1.932 doi: 10.1007/s00192-023-05462-z. 

Raina J, Bastrash M-P, Suarthana E, Larouche M. Perioperative complication rates of colpocleisis performed with or without hysterectomy a large population-based study. Int Urogynecol J. 2023. May;34(5):1111-1118. PMID: 36705729. (IF 1.932).  doi: 10.1007/s00192-023-05457-w

Busque AA, Belzile E, Rodrigues K, Larouche M. Major perioperative complications of benign gynecologic procedures at a university-affiliated hospital. McGill Journal of Medicine 2022, 21(6):1-12.

Nguyen LN, Randhawa H, Nadeau G, Cox A, Hickling D, Campeau L, Li J, Welk B, Carlson K. Canadian Urological Association best practice report: diagnosis and management of nocturia. Canadian Urological Association Journal. 2022 Jul;16(7): E336-349. PMID: 35819914. DOI: 10.5489/cuaj.7970

Cammisotto PG, Mossa AH, Shamout S, Campeau L. Urinary levels of miR-491-5p and miR-592 as potential diagnostic biomarkers in female aging patients with OAB: a pilot study. Metabolites 2022 Aug 31;12(9):820. PMID: 36144224. DOI: 10.3390/metabo12090820

Covarrubias C, Cammisotto PG, Shamout S, Campeau L. Decrease in the ratio proBDNF/BDNF in the urine of aging female patients with OAB. Metabolites 2023 Jun 3;13(6):723.  PMID: 37367881.

DOI: 10.3390/metabo13060723

Bouchard, B., Campeau, L. Quality, Value, and Efficacy of Complementary and Alternative Medicine in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome. Curr Bladder Dysfunct Rep 18, 51–58 (2023).

McGill University 

Research Spotlight

Publication Highlight

Covarrubias C, Cammisotto PG, Shamout S, Campeau L. Decrease in the ratio proBDNF/BDNF in the urine of aging female patients with OAB. Metabolites 2023 Jun 3;13(6):723.  PMID: 37367881. DOI: 10.3390/metabo13060723

An indisputable link exists between neurotrophins and growth factors (i.e., nerve growth factor/NGF, its precursor, proNGF), and overactive bladder syndrome (OAB). Thus, the team of Dr Lysanne Campeau, Associate Professor of Surgery at McGill University, first aimed to develop a non-invasive tool for diagnosing OAB syndrome in the urine of aging women. MicroRNAs related to NGF and proNGF metabolism (miR-491-5p and miR-592) that negatively control the translation of the matrix metalloproteinase-9 (MMP-9, the primary enzyme degrading NGF) were detected in void urine. Levels of miR-491-5p, the main miRNA that downregulates MMP-9 synthesis, were significantly decreased in urine from OAB patients. Next, concentrations of brain-derived neurotrophic factor (BDNF) and its precursor (proBDNF) were measured in the urine of a cohort of aging female patients with OAB. The ratio of proBDNF/BDNF was significantly decreased in the OAB group, while the level of MMP-9, the enzyme that cleaves proBDNF into BDNF, was increased in OAB compared to controls. These results suggest that neurotrophins are regulated at the levels of proteolytic enzymes converting pro-form to mature form rather than the translational levels; the ratio proBDNF/BDNF could be useful in the phenotyping of OAB in an aging population, and the difference could originate from enhanced MMP-9 enzymatic activity. Their studies confirm the diagnostic and phenotyping value of the urinary ratio proBDNF over mature BDNF. 

2022-2023 Publication List

Kakkar A, Reuveni-Salzman A, Bentaleb J, Belzile E, Merovitz L, Larouche M. Adverse events associated with pessary use over one year among women attending a pessary care clinic. Int Urogynecol J. 2023. Aug;34(8):1765-1770. PMID: 36715742. IF 1.932 doi: 10.1007/s00192-023-05462-z. 

Raina J, Bastrash M-P, Suarthana E, Larouche M. Perioperative complication rates of colpocleisis performed with or without hysterectomy a large population-based study. Int Urogynecol J. 2023. May;34(5):1111-1118. PMID: 36705729. (IF 1.932).  doi: 10.1007/s00192-023-05457-w

Busque AA, Belzile E, Rodrigues K, Larouche M. Major perioperative complications of benign gynecologic procedures at a university-affiliated hospital. McGill Journal of Medicine 2022, 21(6):1-12.

Nguyen LN, Randhawa H, Nadeau G, Cox A, Hickling D, Campeau L, Li J, Welk B, Carlson K. Canadian Urological Association best practice report: diagnosis and management of nocturia. Canadian Urological Association Journal. 2022 Jul;16(7): E336-349. PMID: 35819914. DOI: 10.5489/cuaj.7970

Cammisotto PG, Mossa AH, Shamout S, Campeau L. Urinary levels of miR-491-5p and miR-592 as potential diagnostic biomarkers in female aging patients with OAB: a pilot study. Metabolites 2022 Aug 31;12(9):820. PMID: 36144224. DOI: 10.3390/metabo12090820

Covarrubias C, Cammisotto PG, Shamout S, Campeau L. Decrease in the ratio proBDNF/BDNF in the urine of aging female patients with OAB. Metabolites 2023 Jun 3;13(6):723.  PMID: 37367881.

DOI: 10.3390/metabo13060723

Bouchard, B., Campeau, L. Quality, Value, and Efficacy of Complementary and Alternative Medicine in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome. Curr Bladder Dysfunct Rep 18, 51–58 (2023).